在患有扩散型大B细胞淋巴瘤的患者中,可溶性编程细胞死亡联体-1的预后和临床病理学作用:元分析

Hongbin Lu1, Lulu Luo1, Jie Mi1

  • 1Department of Hematology, Wuxi Branch of Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Wuxi, Jiangsu, China.

Frontiers in oncology
|February 17, 2025
PubMed
概括

升的可溶性编程死亡蛋白联体-1 (sPD-L1) 表明扩散型大B细胞淋巴瘤 (DLBCL) 患者的预后较差,与总生存率和无进展生存率的降低相关. 较高的sPD-L1与更具侵略性的疾病特征有关.